PMID- 23332451
OWN - NLM
STAT- MEDLINE
DCOM- 20130813
LR  - 20220408
IS  - 1879-114X (Electronic)
IS  - 0149-2918 (Linking)
VI  - 35
IP  - 2
DP  - 2013 Feb
TI  - Efficacy and tolerability of febuxostat in hyperuricemic patients with or without 
      gout: a systematic review and meta-analysis.
PG  - 180-9
LID - S0149-2918(12)00723-0 [pii]
LID - 10.1016/j.clinthera.2012.12.011 [doi]
AB  - BACKGROUND: Febuxostat has been approved for the treatment of hyperuricemia in 
      patients with/without gout. OBJECTIVES: This meta-analysis and systematic review 
      assessed the efficacy and tolerability of febuxostat in hyperuricemic patients 
      with/without gout. METHODS: Major electronic databases were searched for articles 
      of all publication years (up to February 2012), as were the Web sites of the 
      American College of Rheumatology, the European League Against Rheumatism, and the 
      Chinese State Food and Drug Administration, and clinicaltrials.gov for 
      unpublished studies. Only randomized, controlled trials (RCTs) were included. 
      RESULTS: Ten trials were included. A significantly greater proportion of patients 
      achieved the target serum urate level (sUA </=6.0 mg/dL) at the final visit in the 
      febuxostat group compared with the placebo (OR = 235.73; P < 0.01) and 
      allopurinol groups (OR = 3.14; P < 0.01). In subgroup analysis, the proportion of 
      patients who achieved target sUA at the final visit was significantly greater in 
      the febuxostat-treated group (40 mg/d) compared with the allopurinol-treated 
      group (100-300 mg/d) (50.9% vs 45.6%; OR = 1.25; 95% CI, 1.05-1.49; P = 0.01). As 
      the dosage was increased (40, 80, 120 mg/d), the proportion of patients who 
      achieved target sUA in the febuxostat-treated group increased gradually (50.9%, 
      71.4%, 82%, respectively). There was no significant difference in the occurrence 
      of adverse events (AEs) between the febuxostat- and allopurinol-treated groups. 
      CONCLUSION: Febuxostat was effective in reducing serum urate in hyperuricemic 
      patients with/without gout, and febuxostat (40-120 mg/d) was more efficacious 
      compared with allopurinol (100-300 mg/d). The doses of allopurinol to which 
      febuxostat has been compared, although commonly prescribed, are low in the range 
      of approved doses of allopurinol. The tolerability of febuxostat for the 
      treatment of hyperuricemia with/without gout is similar to that of allopurinol.
CI  - Copyright (c) 2013 Elsevier HS Journals, Inc. All rights reserved.
FAU - Ye, Peng
AU  - Ye P
AD  - Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, People's Republic of China.
FAU - Yang, Shumin
AU  - Yang S
FAU - Zhang, Wenlong
AU  - Zhang W
FAU - Lv, Qiong
AU  - Lv Q
FAU - Cheng, Qingfeng
AU  - Cheng Q
FAU - Mei, Mei
AU  - Mei M
FAU - Luo, Ting
AU  - Luo T
FAU - Liu, Lulu
AU  - Liu L
FAU - Chen, Shumei
AU  - Chen S
FAU - Li, Qifu
AU  - Li Q
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20130116
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Gout Suppressants)
RN  - 0 (Thiazoles)
RN  - 101V0R1N2E (Febuxostat)
RN  - 268B43MJ25 (Uric Acid)
RN  - 63CZ7GJN5I (Allopurinol)
SB  - IM
MH  - Allopurinol/therapeutic use
MH  - Febuxostat
MH  - Gout/*epidemiology
MH  - Gout Suppressants/administration & dosage/adverse effects/*therapeutic use
MH  - Humans
MH  - Hyperuricemia/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Thiazoles/administration & dosage/adverse effects/*therapeutic use
MH  - Uric Acid/blood
EDAT- 2013/01/22 06:00
MHDA- 2013/08/14 06:00
CRDT- 2013/01/22 06:00
PHST- 2012/09/20 00:00 [received]
PHST- 2012/12/14 00:00 [revised]
PHST- 2012/12/18 00:00 [accepted]
PHST- 2013/01/22 06:00 [entrez]
PHST- 2013/01/22 06:00 [pubmed]
PHST- 2013/08/14 06:00 [medline]
AID - S0149-2918(12)00723-0 [pii]
AID - 10.1016/j.clinthera.2012.12.011 [doi]
PST - ppublish
SO  - Clin Ther. 2013 Feb;35(2):180-9. doi: 10.1016/j.clinthera.2012.12.011. Epub 2013 
      Jan 16.